



Cancer Steering Committee Annual Meeting

Marriott Bethesda North Conference Center, Bethesda, MD

Thursday, December 15, 2016

7:45 am – 7:00 pm

Friday, December 16, 2016

7:30 am – 3:15 pm

Agenda

Thursday, December 15

7:45 am	Registration and Coffee
8:15 am	FNIH Welcome —Joe Menetski and Stacey Adam
8:40 am	Meeting Introduction —Eric Rubin and Gary Kelloff
8:45 am	Keynote —Bruce Johnson - Perspective on Precision Medicine in Oncology
9:15 am	Meeting Overview —Gary Kelloff - It's about the Biomarker
9:45 am	<p>Strategic Collaborations in Support of Precision Medicine in Oncology Chair: Bruce Johnson</p> <ul style="list-style-type: none"> • Precision Oncology in the VA—Mike Kelley (10') • NCI Precision Medicine Trials (MATCH, Lung-MAP, ALCHEMIST)—Jeff Abrams (10') • Oncology Research Information Exchange Network (ORIEN) Avatar to Accelerate Cancer Research and Improve Treatment— Hongyue Dai (10') • Clinical Proteomic Tumor Analysis Consortium (CPTAC) and VA/DoD/NCI Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) Research Programs —Henry Rodriguez (10') • Partnership for Accelerating Cancer Therapies (PACT)—Helen Chen (10') • Genomic Data Commons (GDC), Project Genomics, Evidence, Neoplasia, Information, Exchange (GENIE)—Gary Kelloff (10') <p>Q&A (15')</p>
11:00 am	Coffee
11:15 am	<p>Minimal Residual Disease in Blood Based Cancers (MRD) Chairs: Ken Anderson, Greg Reaman</p> <ul style="list-style-type: none"> • MRD in ALL Project Summary—Kim Jessup (10') MRD in Acute Lymphocytic Leukemia (ALL)—Greg Reaman (15') • MRD in Multiple Myeloma—Perspectives and Next Steps—Ken Anderson (15') MRD in Myeloma Project Summary, Master Protocol—Daniel Auclair (15') • MRD in Acute Myeloid Leukemia— John Byrd (15') <p>Roundtable Discussion: Definition, Evaluation and Application of MRD to Drug Development and Patient Care in Blood Based Cancers (35')</p> <p>Moderator: Kim Jessup Panelists: Ken Anderson, Daniel Auclair, John Byrd, Don Berry, Ann Farrell, Gary Gordon, Nicole Gormley, Mike Keeney, Lanny Kirsch, Nancy Valente, Shaji Kumar, Rich Little, Greg Reaman</p>
1:00 pm	Lunch

<p>1:30 pm</p>	<p>Imaging Based Biomarkers Chair: Larry Schwartz</p> <ul style="list-style-type: none"> • Vol-PACT—Background, Rationale, Imaging Endpoints, Modeling, Progress —Larry Schwartz (20’) • Improving Imaging Data and Technology for Oncologic Drug Development and Patient Care—Geoff Oxnard (10’) • FDG-PET Assessment of Treatment Response in the CALGB/Alliance Phase III Study of R-CHOP vs. Dose-adjusted EPOCH-R in Untreated DLBCL—Mike Knopp (10’) • NCI’s Cancer Imaging Archive, An Exploratory Resource—Paula Jacobs (10’) • Radiomics—Larry Schwartz (10’) • Quantitative Imaging Network/Superpixels — Bob Nordstrom(10’) <p>Roundtable Discussion: Technologies and Resources for Development of Imaging Based Biomarkers - 20’)</p> <p>Moderator: Gideon Blumenthal Panelists: Larry Schwartz, Paula Jacobs, Bruce Johnson, Michael O’Neal, Dan Sullivan, Pat Cole, Andrea Perrone, Dinko Trotter, Michael Maitland</p>
<p>3:00 pm</p>	<p>High Content Data Working Group Project Concept Update— Keith Ligon/Scott Manalis – Mass and Growth Biomarkers for Precision Medicine</p>
<p>3:30 pm</p>	<p>Break</p>
<p>3:45 pm</p>	<p>Liquid Biopsy—Cancer Biology, Analytical & Clinical Validation, Clinical Utility Co-Chairs: Jerry Lee, Andrew Schade</p> <ul style="list-style-type: none"> • Perspectives on Blood Biomarker Development—Dan Hayes (15’) • HD-SCA in Metastatic Colorectal Cancer—Peter Kuhn (10’) • Blood Profiling Atlas (for ctDNA, CTC, Exosomes)—Lauren Leiman (10’) • ctDNA Reference Standards <ul style="list-style-type: none"> — Partners, Workforce Structure, Products—Robert McCormack (10’) — Components of Reference Materials, Analytical Validation of ctDNA Assays—Mickey Williams (10’) — Perspectives on Clinical Validation of Reference Standards – Geoff Oxnard (10’) • Overview of Project to Validate and Define Clinical Utility of Liquid Biopsies (ctDNA, CTC, Exosomes)—Minetta Liu (10’) • Clinical Protocols to Demonstrate Value of Liquid Biopsies for Drug Development and Patient Care— Pilot and Confirmatory Clinical Trial Designs for Clinical Validation and Clinical Utility: <ul style="list-style-type: none"> — Breast Cancer, Melanoma—Minetta Liu (20’) — Prostate Cancer—Howard Scher (15’) — Lung Cancer—Vali Papadimitrakopoulou (10’) <p>Roundtable Discussion: Clinical Validation and Determination of Clinical Utility of ctDNA, CTC and Exosome Assays (30’)</p> <p>Moderator: Carl Barrett Panelists: Anahita Bhatena, Gideon Blumenthal, Ken Cole, Lauren Leiman, Liz Mansfield, Vali Papadimitrakopoulou, Reena Philip, Bob Becker, Minetta Liu, Bob McCormack, Tracy Lively, Jerry Lee, Andrew Schade</p>
<p>6:15 pm</p>	<p>Break</p>
<p>6:30 pm</p>	<p>Keynote - Doug Lowy - Cancer Research in the Cancer Moonshot Era</p>
<p>7:00 pm</p>	<p>Reception</p>
<p>8:00 pm</p>	<p>Adjourn</p>

Friday, December 16

7:30 am	Registration and Breakfast
7:50 am	Meeting Overview II—Eric Rubin
8:00 am	Keynote—David Rimm - Protein Biomarkers for Companion Diagnostic Tests: Science, not Cooking and Getting to N>1
8:30 am	<p>Immuno-oncology Biomarkers—Project Opportunities Chair: Eric Rubin</p> <ul style="list-style-type: none"> • Determining the Impact of Chemotherapy on Tumor Immunity by Systematic Dissection of the Tumor Microenvironment with Single Cell Genomics— Orit Rozenblatt-Rosen (25') • Immunosequencing in the Service of Immuno-oncology—Lanny Kirsch (15') • Curative Potential of T-cell Immunotherapy for Cancer—Steven Rosenberg (15') • MD Anderson Moonshot Program and Immunotherapy Trials — Ignacio Wistuba (15') • Immune System Metabolomics—Jeff Rathmell (15') <p>Roundtable Discussion (35'): Which immune system related biomarkers will be useful for drug development and patient management?</p> <p>Moderator: Marc Theoret Panelists: Lisa Butterfield, Michele Cleary, Priti Hegde, Rob Iannone, Ramy Ibrahim, David Kaufman, Reena Philip, Elad Sharon, Howard Streicher, Magdalena Thurin, Percy Ivy, Eric Rubin, Steven Rosenberg</p>
10:30 am	Break
10:45 am	<p>Big Data—Data Standardization, Harmonization, and Sharing Chairs: Richard Schilsky, Warren Kibbe</p> <ul style="list-style-type: none"> • Challenges of Data Sharing in Oncology <ul style="list-style-type: none"> — Cloud Pilots – Warren Kibbe – (10') — APOLLO Implementation Plan—Louis Fiore (10') — FDA INFORM – Sean Khozin – (10') — Data sharing plans for TAPUR and CancerLinQ – Richard Schilsky – (10') — Project Datasphere – Monica Bertagnolli – (10') — A Public-Private Partnership Leveraging Physician Quality Reporting System Outcomes and Translational Genomics Research – Bill Catalona – (10') <p>Q&A (15')</p>
12:00 pm	Lunch
12:30 pm	<p>Big Data—Data Standardization, Harmonization, and Sharing Roundtable Discussion: What are the largest challenges to be overcome to allow for necessary data sharing in oncology? What strategies can be employed?</p> <p>Moderator: Warren Kibbe Panelists: Zach Weinberg, Bill Catalona, Lou Fiore, Paula Jacobs, Sean Khozin, Lauren Leiman, Marty Murphy, Marc Theoret, Raji Sridhara, Rich Schilsky, Monica Bertagnolli</p>
1:15 pm	Keynote—Chris Austin - Catalyzing Translational Innovation

<p>1:45 pm</p>	<p>Cross-Disease Analysis of Biomarker Initiatives—Analogies, Synergies, Approaches for Collaboration</p> <ul style="list-style-type: none"> • FDA Perspective on Biomarker Development – Joe Menetski – (20') Q&A (10') • Presentations from Other Biomarker Consortium Portfolios <ul style="list-style-type: none"> — Inflammation and Immunity Steering Committee Update/Metabolic Disorders Steering Committee Update – Steve Hoffmann – (20') — Neuroscience Steering Committee Update – Rosa Canet-Aviles – (10') <p>Round Table: Potential opportunities for cross-disease biomarker development collaborations- (30')</p> <p>Moderator: Eric Rubin Panelists: Anahita Bhatena, Danilo Tagle, Greg Friberg, Gary Kelloff, Joe Menetski Steve Hoffman, Rosa Canet-Aviles, Michele Cleary, Steffan Ho</p>
<p>3:15 pm</p>	<p>Adjourn</p>